Chinese Spondyloarthritis Inception Cohort (CESPIC)

Army Medical University

Status: Not yet enrolling

Conditions: Reactive Arthritis (ReA); Acute Anterior Uveitis (AAU); Axial Psoriatic Arthritis (axPsA); Non-radiographic Axial Spondyloarthritis (Nr-axSpA); Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA); Ulcerative Colitis (UC); Crohn Disease (CD)

Treatments: Drug: Celecoxib

Study type: Observational

Funder types: Other

Identifiers

NCT05960864

CESPIC

Details and patient eligibility

About

The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Crohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis.

Exclusion criteria

Infections, Malignancies, Major cardiovascular events, Lower intestinal perforations Other adverse events

Trial design

1,000 participants in 7 patient groups

Ankylosing spondylitis

Description:

Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist

Treatment:

Drug: Celecoxib

Non-radiographic axial spondyloarthritis

Description:

Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist

Treatment:

Drug: Celecoxib

Juvenile spondyloarthritis

Description:

Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).

Treatment:

Drug: Celecoxib

Crohn's disease

Description:

Patients with Crohn's disease

Treatment:

Drug: Celecoxib

Acute anterior uveitis

Description:

Patients with acute anterior uveitis

Treatment:

Drug: Celecoxib

Axial psoriatic arthritis

Description:

Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)

Treatment:

Drug: Celecoxib

Reactive arthritis

Description:

Patients with reactive arthritis

Treatment:

Drug: Celecoxib